Katherine E Hutchinson

12PUBLICATIONS
113CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Jul 08, 2025
KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).

Kyung W Song, Christy C Ong, Eva Lin

|Sep 05, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard

|Apr 10, 2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.

Arash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia

|Mar 09, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.

Jessica W Chen, William Jacot, Javier Cortés

|Jan 03, 2023
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.

Smruthy Sivakumar, Dexter X Jin, Ruchita Rathod

Pageof 2

Frequent Collaborators

3 joint publications

Jessica W Chen

2 joint publications

Thomas J Stout

2 joint publications

Ethan S Sokol

2 joint publications

Monica V Estrada